Laser Leader

Written by GSCR Staff   
Tuesday, 23 April 2013 08:55

Good Morning.

Today’s featured stock is BIOLASE, Inc. (NASDAQ – BIOL - $5.15).  The Company provides innovative solutions in laser technology for dentistry and general medicine.  Its Waterlase systems are used for cutting tissue matter, and its diode laser system is used in soft tissue, pain therapy, and cosmetic procedures, like teeth whitening.

  BIOL has specialized dental laser systems that permit dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a range of dental procedures, including cosmetic and complex surgical applications.  The Diolase 10 Diode is a specialty product that is used for a variety of pain relief applications.

Why do we think the stock will continue the ride it has had from early February, up over 100%?

First, BIOLASE continues to create and innovate.  The Company was granted two patents within a few days apart last week.  Its non-contact laser piece should offer a competitive edge since it is designed to emit high-density uniform laser beam from a non-contact laser hand piece that is replaceable and can be configured to optimal distances and focal spot sizes.  Also, the FDA cleared Biolase’s EPIC 10S soft tissue diode.  The laser has been cleared in 19 markets and 80 different indications including plastic surgery, oral surgery, orthopedics, dermatology, podiatry, gynecology, cardiac surgery, urology, thoracic surgery, vascular surgery, aesthetics, ophthalmology, general surgery, and ear, nose and throat among others. Additionally, this product is also cleared by the FDA for temporary pain relief and tooth whitening.

Additionally, BIOL continues to find new revenue streams.  Last week, it entered into an agreement with Lambda S.p.A., in which Lambda will pay BIOLASE royalties on past and future sales that utilize the ErYAG (erbium-doped yttrium aluminum garnet) laser technology.  The Company also expanded its offerings into CAD/CAM (Computer Aided Design/Computer Aided Manufacturing). 

BIOL clobbered the earning expectations for 4Q12 earnings, reporting $0.05 EPS versus the $0.00 expectation, and $19 million in revenue versus the $18 million estimate.  2013 revenue estimates are expected to be right around the $70 million mark, nearly a 23% increase from 2012.

Add in some very bullish short term charts and BIOL is set to jump to the $6.50 level sometime in this quarter.

Have a great day!

Disclosure: Goldman Small Cap Research analysts are neither long nor short these shares but may elect to purchase the stock within the next 48 hours.

Disclaimer:

This Market Monitor blog was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research, which typically highlights small cap companies, and Goldman Opportunity Research, which features micro cap companies in a sponsored research format. Thus, the Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports. 

It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations. 

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.

ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS   INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com

Add comment
  • No comments found